Frequency of allergic or hematologic adverse reactions to ticlopidine among patients with allergic or hematologic adverse reactions to clopidogrel

Juzar O. Lokhandwala, Patricia Best, Joseph H. Butterfield, Kimberly A. Skelding, Thomas Scott, James C. Blankenship, Jeremy W. Buckley, Peter B. Berger

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Background-Clopidogrel and ticlopidine are structurally very similar. In patients with an allergic or hematologic adverse reaction to either one of these drugs, the likelihood that an allergic or hematologic adverse effect will develop to the other is unknown. It is also unknown whether a reaction to the second thienopyridine is likely to be life threatening. Methods and Results-Medical records from 2 academic institutions were reviewed to identify patients who had an allergic or hematologic adverse reaction to either of the 2 currently commercially available thienopyridines and who were subsequently prescribed the other thienopyridine. Patient demographics, details of the adverse reactions, and subsequent clinical course were reviewed. A total of 76 patients were identified with an allergic or hematologic adverse reaction to clopidogrel or ticlopidine who had also received the other thienopyridine. Fourteen (27%; 95% CI, 16 to 41) patients who had an allergic or hematologic adverse reactions to clopidogrel had a similar reaction to ticlopidine; none developed a life-threatening reaction. The most common reaction was a rash (93%). Conclusions-In patients with an allergic or hematologic adverse reaction to one thienopyridine, there seems to be an increased frequency of such reactions to the other thienopyridine. However, no patient had a life-threatening reaction after exposure to the alternative thienopyridine. (Circ Cardiovasc Intervent. 2009;2:348-351.)

Original languageEnglish (US)
Pages (from-to)348-351
Number of pages4
JournalCirculation: Cardiovascular Interventions
Volume2
Issue number4
DOIs
StatePublished - Aug 2009

Fingerprint

clopidogrel
Ticlopidine
Thienopyridines
Exanthema
Medical Records
thienopyridine

Keywords

  • Allergy
  • Clopidogrel
  • Cross-reactivity
  • Hemorrhage
  • Platelet aggregation inhibitors
  • Thienopyridine
  • Ticlopidine

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Frequency of allergic or hematologic adverse reactions to ticlopidine among patients with allergic or hematologic adverse reactions to clopidogrel. / Lokhandwala, Juzar O.; Best, Patricia; Butterfield, Joseph H.; Skelding, Kimberly A.; Scott, Thomas; Blankenship, James C.; Buckley, Jeremy W.; Berger, Peter B.

In: Circulation: Cardiovascular Interventions, Vol. 2, No. 4, 08.2009, p. 348-351.

Research output: Contribution to journalArticle

Lokhandwala, Juzar O. ; Best, Patricia ; Butterfield, Joseph H. ; Skelding, Kimberly A. ; Scott, Thomas ; Blankenship, James C. ; Buckley, Jeremy W. ; Berger, Peter B. / Frequency of allergic or hematologic adverse reactions to ticlopidine among patients with allergic or hematologic adverse reactions to clopidogrel. In: Circulation: Cardiovascular Interventions. 2009 ; Vol. 2, No. 4. pp. 348-351.
@article{320559d136d4442cac3798430d828e01,
title = "Frequency of allergic or hematologic adverse reactions to ticlopidine among patients with allergic or hematologic adverse reactions to clopidogrel",
abstract = "Background-Clopidogrel and ticlopidine are structurally very similar. In patients with an allergic or hematologic adverse reaction to either one of these drugs, the likelihood that an allergic or hematologic adverse effect will develop to the other is unknown. It is also unknown whether a reaction to the second thienopyridine is likely to be life threatening. Methods and Results-Medical records from 2 academic institutions were reviewed to identify patients who had an allergic or hematologic adverse reaction to either of the 2 currently commercially available thienopyridines and who were subsequently prescribed the other thienopyridine. Patient demographics, details of the adverse reactions, and subsequent clinical course were reviewed. A total of 76 patients were identified with an allergic or hematologic adverse reaction to clopidogrel or ticlopidine who had also received the other thienopyridine. Fourteen (27{\%}; 95{\%} CI, 16 to 41) patients who had an allergic or hematologic adverse reactions to clopidogrel had a similar reaction to ticlopidine; none developed a life-threatening reaction. The most common reaction was a rash (93{\%}). Conclusions-In patients with an allergic or hematologic adverse reaction to one thienopyridine, there seems to be an increased frequency of such reactions to the other thienopyridine. However, no patient had a life-threatening reaction after exposure to the alternative thienopyridine. (Circ Cardiovasc Intervent. 2009;2:348-351.)",
keywords = "Allergy, Clopidogrel, Cross-reactivity, Hemorrhage, Platelet aggregation inhibitors, Thienopyridine, Ticlopidine",
author = "Lokhandwala, {Juzar O.} and Patricia Best and Butterfield, {Joseph H.} and Skelding, {Kimberly A.} and Thomas Scott and Blankenship, {James C.} and Buckley, {Jeremy W.} and Berger, {Peter B.}",
year = "2009",
month = "8",
doi = "10.1161/CIRCINTERVENTIONS.108.832964",
language = "English (US)",
volume = "2",
pages = "348--351",
journal = "Circulation: Cardiovascular Interventions",
issn = "1941-7640",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Frequency of allergic or hematologic adverse reactions to ticlopidine among patients with allergic or hematologic adverse reactions to clopidogrel

AU - Lokhandwala, Juzar O.

AU - Best, Patricia

AU - Butterfield, Joseph H.

AU - Skelding, Kimberly A.

AU - Scott, Thomas

AU - Blankenship, James C.

AU - Buckley, Jeremy W.

AU - Berger, Peter B.

PY - 2009/8

Y1 - 2009/8

N2 - Background-Clopidogrel and ticlopidine are structurally very similar. In patients with an allergic or hematologic adverse reaction to either one of these drugs, the likelihood that an allergic or hematologic adverse effect will develop to the other is unknown. It is also unknown whether a reaction to the second thienopyridine is likely to be life threatening. Methods and Results-Medical records from 2 academic institutions were reviewed to identify patients who had an allergic or hematologic adverse reaction to either of the 2 currently commercially available thienopyridines and who were subsequently prescribed the other thienopyridine. Patient demographics, details of the adverse reactions, and subsequent clinical course were reviewed. A total of 76 patients were identified with an allergic or hematologic adverse reaction to clopidogrel or ticlopidine who had also received the other thienopyridine. Fourteen (27%; 95% CI, 16 to 41) patients who had an allergic or hematologic adverse reactions to clopidogrel had a similar reaction to ticlopidine; none developed a life-threatening reaction. The most common reaction was a rash (93%). Conclusions-In patients with an allergic or hematologic adverse reaction to one thienopyridine, there seems to be an increased frequency of such reactions to the other thienopyridine. However, no patient had a life-threatening reaction after exposure to the alternative thienopyridine. (Circ Cardiovasc Intervent. 2009;2:348-351.)

AB - Background-Clopidogrel and ticlopidine are structurally very similar. In patients with an allergic or hematologic adverse reaction to either one of these drugs, the likelihood that an allergic or hematologic adverse effect will develop to the other is unknown. It is also unknown whether a reaction to the second thienopyridine is likely to be life threatening. Methods and Results-Medical records from 2 academic institutions were reviewed to identify patients who had an allergic or hematologic adverse reaction to either of the 2 currently commercially available thienopyridines and who were subsequently prescribed the other thienopyridine. Patient demographics, details of the adverse reactions, and subsequent clinical course were reviewed. A total of 76 patients were identified with an allergic or hematologic adverse reaction to clopidogrel or ticlopidine who had also received the other thienopyridine. Fourteen (27%; 95% CI, 16 to 41) patients who had an allergic or hematologic adverse reactions to clopidogrel had a similar reaction to ticlopidine; none developed a life-threatening reaction. The most common reaction was a rash (93%). Conclusions-In patients with an allergic or hematologic adverse reaction to one thienopyridine, there seems to be an increased frequency of such reactions to the other thienopyridine. However, no patient had a life-threatening reaction after exposure to the alternative thienopyridine. (Circ Cardiovasc Intervent. 2009;2:348-351.)

KW - Allergy

KW - Clopidogrel

KW - Cross-reactivity

KW - Hemorrhage

KW - Platelet aggregation inhibitors

KW - Thienopyridine

KW - Ticlopidine

UR - http://www.scopus.com/inward/record.url?scp=74549116585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74549116585&partnerID=8YFLogxK

U2 - 10.1161/CIRCINTERVENTIONS.108.832964

DO - 10.1161/CIRCINTERVENTIONS.108.832964

M3 - Article

VL - 2

SP - 348

EP - 351

JO - Circulation: Cardiovascular Interventions

JF - Circulation: Cardiovascular Interventions

SN - 1941-7640

IS - 4

ER -